BIOMÉRIEUX

VIDAS® TB-IGRA

FULLY AUTOMATED TESTING SOLUTION

PIONEERING DIAGNOSTICS

Did you know?

LATENT TUBERCULOSIS, A HUGE RESERVOIR FOR A DEADLY DISEASE

Tuberculosis (TB) :
one of the top deadliest infectious disease worldwide

1/4 of people worldwide are **infected with latent TB**

Without treatment, **10-15%** of them are at risk to develop active **TB disease**

DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION (LTBI)

A priority to:
- Prevent the development of TB disease
- Stop the spread of TB

CURRENT TB-IGRA TESTS ARE CUMBERSOME

SEVERAL STEPS & TUBES | **NO GOLD STANDARD** | **HANDS-ON-TIME**

WHAT IF YOU HAD ACCESS TO AN EASIER AND FULLY AUTOMATED TB-IGRA SOLUTION?

VIDAS® TB-IGRA

RELIABLE RESULTS FOR TB INFECTION

MORE CONFIDENCE IN IDENTIFYING INFECTED PEOPLE

HIGH SENSITIVITY
ON ACTIVE TB POPULATION*

VIDAS® TB-IGRA sensitivity

97.5% vs. **80.7%** for QFT®-Plus

The VIDAS® TB-IGRA assay gave
- **more true-positive results,**
- **fewer false-negative results,**

than the comparative assay.

HIGH SPECIFICITY
ON POPULATION AT EXTREMELY LOW LEVEL OF TB INFECTION**

VIDAS® TB-IGRA specificity

97.6% vs. **95.2%** for QFT®-Plus

High capacity to identify active TB patients and non-TB-infected patients

STRONG AGREEMENT WITH COMPARABLE SOLUTION***
ON POPULATION WITH MIXED RISK OF TB INFECTION

92.1% **VIDAS® Positive Percent Agreement (PPA)**

90.1% **VIDAS® Negative Percent Agrement (NPA)**

As there is no gold standard for the diagnosis of individuals with Latent TB Infection (LTBI), PPA and NPA with a comparative assay were determined.

* Evaluated on culture-confirmed active TB patients excluding indeterminate results
** Blood donors from a low endemic country considered at extremely low risk of TB infection
*** Compared to QuantiFERON®-TB Gold Plus test (QFT®-Plus)

VIDAS® TB-IGRA

FULLY AUTOMATED SOLUTION

FOR IMPROVED PATIENT MANAGEMENT

Positive results of the **VIDAS® TB-IGRA** (■)
versus QFT®-Plus (■) in the Mixed Risk population



Globally the rate of positive results was statistically higher (α=5%) for the VIDAS® TB-IGRA assay than for the QFT®-Plus assay (p-value < 0.0001).

Detect more TB-infected individuals as risk becomes higher

As the TB-exposure risk increases, VIDAS® TB-IGRA detects more positive samples reflecting a stronger association with the expected likelihood of Latent TB Infection***.

REDUCE CHALLENGES LINKED TO INDETERMINATE RESULTS

Analysis on indeterminate results

	VIDAS® TB-IGRA	QFT®-Plus
Indeterminate	0.1% (2/1660)	1.2% (20/1660)

The rate of indeterminate results was statistically lower (α=5%) for the VIDAS® TB-IGRA assay than for the QFT®-Plus assay (p-value = 0.0001).

VIDAS® TB-IGRA assay provides fewer indeterminate results*** : **high capacity to give valid, interpreted results to clinicians.**

Reliable results for TB infection, greater ability to detect *Mycobacterium tuberculosis* infected persons

OPTIMIZE YOUR WORKFLOW

ALL STEPS MANAGED INSIDE THE VIDAS® 3 from a single whole blood tube



EASY TB-IGRA TESTING SOLUTION

- No multiple tubes to handle
- No sample preparation
- Simply load & go

GOOD ANALYTICAL PRECISION*

- The repeatability estimates (CV%) < 10.0%

TAKE CONTROL OF YOUR TB-IGRA testing with VIDAS® 3

- **MINIMAL HANDS-ON-TIME**
  Easy to use, simple process
- **QUICK TIME TO RESULT**
  Results available in 1 day
- **COST-EFFECTIVE**
  All materials included in the kit (calibration, controls)

SAVE TIME, AND TURNAROUND TIME

* Compared to currently available IGRA tests



AVAILABLE ON VIDAS® 3

BECAUSE IT MAKES SENSE ON VIDAS®

Easily manage TB testing within your activity

24/7 On-demand automated testing

100% automated & enhanced traceability

Save time

All-inclusive kits, limited calibrations and controls

Robust MTBF>700 days

	VIDAS® TB-IGRA	VIDAS® IFNg QC PANEL
Reference	423111	424069
Tests / kit	20 TB-IGRA tests 3 strips/SPR for 1 Patient test	N/A
Kit content	60 strips and 60 SPR S1, C1 Stimulation reagents	4 lyophilized vials (4x3 mL) 2 x IFNg QC1 x 3 mL 2 x IFNg QC2 x 3mL
Time to result	17h for 1 patient	43 min
Sample type	Whole blood (lithium heparin tube)	lyophilized recombinant human IFN-γ
Sample volume	300 µL x 3 (for the 3 strips)	150 µL
Calibration frequency	56 days	
Calibration protocol	43 minutes	

REFERENCES

1. https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
2. https://www.ecdc.europa.eu/en/tuberculosis.
3. VIDAS®TB-IGRA (Ref : 423111) Package insert 053331.
4. Clinical Trials.

bioMérieux S.A. • 69280 Marcy l'Etoile • France • Tel.: + 33 (0)4 78 87 20 00
www.biomerieux.com